We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

PHC Europe

PHC Europe BV, part of the PHC Corporation, Biomedical Division, manages sales, marketing, logistics and technical se... read more Featured Products: More products

Download Mobile App




Benchtop Immunoanalyzer Delivers Lab Quality Results for Cardiology, Intensive Care and Emergency Wards at POC

By LabMedica International staff writers
Posted on 24 Nov 2022

A compact immunoanalyzer with superior assay performance combines the accuracy of a full-scale lab analyzer with the flexibility of a mobile solution, making it an ideal analysis system for laboratories, hospitals and medical offices where fast quantitative results (with full-scale lab quality) are required at the point of care. More...

The PATHFAST system from PHC Europe BV (Etten Leur, The Netherlands) is a fully automatic immunoassay analyzer, which combines the progressive chemiluminescence technology with the patented Magtration technology. PATHFAST provides fast, differential diagnosis and is easy to operate, install and network. Its high precision makes the analyzer an adequate “satellite” of a full-scale lab on a cardiology, intensive care or emergency ward. Parallel processing enables the examination of six samples in only a few minutes from whole blood, serum or plasma.

Six parallel channels give PATHFAST its unique speed with the ability to test for up to six different markers or a single marker for one or more patients’ samples in the same run. Whole blood can be used as sample material, eliminating laborious centrifuge routine, while plasma and serum can also be used. The use of whole blood saves time in obtaining the results while the patient is still at the point of care. Small sample volumes can be detected with high accuracy and precision. The device and the reagent strips provide optimum sensitivity. With its easy and intuitive design, PATHFAST offers an easy way to analyze patient samples by performing only three simple steps. The results are perfectly reproducible and correlate outstandingly with lab analysis.

Always safe and perfectly efficient, PATHFAST processes patient samples automatically and generates lab quality results without the need for additional reagents, buffer solutions or accessories (e.g. capillaries, cuvettes). It does not require water connection and drain, or any special skills, with only short training being sufficient to operate the PATHFAST. Other practical advantages are its highest operating safety and minimum maintenance expense.

Related Links:
PHC Europe BV


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.